News

Mild CKD Ups Risks of Renal, Urothelial Cancers


 

FROM THE GENITOURINARY CANCERS SYMPOSIUM

The Genitourinary Cancers Symposium is sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology.

Dr. Lowrance disclosed that he had no relevant conflicts of interest. Dr. Hutson disclosed that he is a consultant to and receives honoraria from Bayer, Genentech, GlaxoSmithKline, Novartis, Onyx, Pfizer, and Wyeth, and that he receives research funding from GlaxoSmithKline, Pfizer, and Wyeth.

Pages

Recommended Reading

Cancer Screening Falls Short of Federal Targets
MDedge Internal Medicine
Head/Neck Cancer Treatments Less Effective in HIV Patients
MDedge Internal Medicine
Re-Excision Rates After Breast-Conserving Surgery Vary Greatly
MDedge Internal Medicine
ASCO GU to Spotlight Prostate Cancer Drugs MDV3100 and Radium-223
MDedge Internal Medicine
MDV3100 Cuts Risk of Death in Advanced Prostate Cancer
MDedge Internal Medicine
ALSYMPCA Trial: Radium-223 Prolongs Life in Some Prostate Cancers
MDedge Internal Medicine
Breast Cancer Drug Exemestane Linked to BMD Loss
MDedge Internal Medicine
Breast Cancer Mortality Rises with Age in Older Women
MDedge Internal Medicine
FDA Panel Rejects Denosumab Against Bone Metastasis in Prostate Cancer
MDedge Internal Medicine
IMRT Provides Better QOL in Head and Neck Cancers
MDedge Internal Medicine